Eischens Yoga in Reducing Fatigue and Stress Levels in Patients with Stage I-II Cancer
This early phase I trial studies how well yoga works in reducing fatigue and stress levels in patients with stage I-II cancer. Yoga decreases pain, reduces stress, and has been shown to improve sleep quality, energy, and physical functioning. Eischens yoga specifically incorporates ideas from movement theory, kinesiology, and Ayurveda, and is more focused on the energy of poses rather than doing more complex poses.
- Stage I and II cancer patients with solid tumors undergoing radiation therapy (RT) for 4-8 weeks (external beam radiation)
- All patients must sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of the University of Pennsylvania
- Patients must be English speaking
- Patients must be able to attend the schedule classes
- Patients with medical restrictions that may interfere with or prevent them from taking part in the yoga interventions per their physician orders
- Patients with metastatic disease
- Active smokers. Smoking may interfere with relaxation and breathing modalities of the yoga interventions. (Self-reporting smokers that have been smoke free for 6 months may be included)
- Patients who currently practice or have recently practiced yoga (had not taken a yoga class on a regular bases in the last 6 months)
Locations & Contacts
Contact: Neha Vapiwala
Trial Objectives and Outline
I. To determine the feasibility of implementing Eischens yoga interventions for solid tumor cancer patients undergoing radiation therapy.
II. To examine the effect of yoga on cancer and radiation related fatigue, and stress levels during radiation therapy.
III. To examine the long term effect of yoga to be tested at the 6 months post radiation visit.
Patients undergo an Eischens yoga session over 75 minutes twice weekly (BIW) for 12 weeks.
After completion of study, patients are followed up for up to 6 months.
Trial Phase & Type
No phase specified
University of Pennsylvania / Abramson Cancer Center
Secondary IDs NCI-2018-03289
Clinicaltrials.gov ID NCT03728205